Cargando…

Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione

CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum and...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Reilly, Michael W., Taylor, Angela E., Crabtree, Nicola J., Hughes, Beverly A., Capper, Farfia, Crowley, Rachel K., Stewart, Paul M., Tomlinson, Jeremy W., Arlt, Wiebke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955250/
https://www.ncbi.nlm.nih.gov/pubmed/24423344
http://dx.doi.org/10.1210/jc.2013-3399
_version_ 1782307545324453888
author O'Reilly, Michael W.
Taylor, Angela E.
Crabtree, Nicola J.
Hughes, Beverly A.
Capper, Farfia
Crowley, Rachel K.
Stewart, Paul M.
Tomlinson, Jeremy W.
Arlt, Wiebke
author_facet O'Reilly, Michael W.
Taylor, Angela E.
Crabtree, Nicola J.
Hughes, Beverly A.
Capper, Farfia
Crowley, Rachel K.
Stewart, Paul M.
Tomlinson, Jeremy W.
Arlt, Wiebke
author_sort O'Reilly, Michael W.
collection PubMed
description CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dysfunction in PCOS. PATIENTS AND METHODS: Eighty-six PCOS patients fulfilling Rotterdam diagnostic consensus criteria and 43 age- and body mass index-matched controls underwent measurement of serum androgens by tandem mass spectrometry and an oral glucose tolerance test with homeostatic model assessment of insulin resistance and insulin sensitivity index calculation. We analyzed 24-hour urine androgen excretion by gas chromatography/mass spectrometry. RESULTS: PCOS patients had higher levels of serum androgens and urinary androgen metabolites than controls (all P < .001). Within the PCOS cohort, both serum A and T were positively correlated with the free androgen index (T × 100/SHBG) and total androgen metabolite excretion (all P < .001). All subjects with T above the normal reference range [high T (HT)] also had high A (HA/HT group, n = 56). However, the remaining 30 patients had normal T levels, either in the presence of HA (HA/NT; n = 20) or normal A (NA/NT; n = 10). The groups did not differ in age or BMI. The HA/HT and HA/NT groups had higher total androgen excretion than NA/NT (P < .01 and P < .05, respectively). Multiple linear regression showed a strong negative association between serum androstenedione and insulin sensitivity. The incidence of dysglycemia according to an oral glucose tolerance test increased with the severity of androgen phenotype (NA/NT, 0%; HA/NT, 14%; HA/HT, 25%, P = .03). CONCLUSION: Simultaneous measurement of serum T and A represents a useful tool for predicting metabolic risk in PCOS women. HA levels are a sensitive indicator of PCOS-related androgen excess.
format Online
Article
Text
id pubmed-3955250
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-39552502014-04-02 Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione O'Reilly, Michael W. Taylor, Angela E. Crabtree, Nicola J. Hughes, Beverly A. Capper, Farfia Crowley, Rachel K. Stewart, Paul M. Tomlinson, Jeremy W. Arlt, Wiebke J Clin Endocrinol Metab Endocrine Research CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dysfunction in PCOS. PATIENTS AND METHODS: Eighty-six PCOS patients fulfilling Rotterdam diagnostic consensus criteria and 43 age- and body mass index-matched controls underwent measurement of serum androgens by tandem mass spectrometry and an oral glucose tolerance test with homeostatic model assessment of insulin resistance and insulin sensitivity index calculation. We analyzed 24-hour urine androgen excretion by gas chromatography/mass spectrometry. RESULTS: PCOS patients had higher levels of serum androgens and urinary androgen metabolites than controls (all P < .001). Within the PCOS cohort, both serum A and T were positively correlated with the free androgen index (T × 100/SHBG) and total androgen metabolite excretion (all P < .001). All subjects with T above the normal reference range [high T (HT)] also had high A (HA/HT group, n = 56). However, the remaining 30 patients had normal T levels, either in the presence of HA (HA/NT; n = 20) or normal A (NA/NT; n = 10). The groups did not differ in age or BMI. The HA/HT and HA/NT groups had higher total androgen excretion than NA/NT (P < .01 and P < .05, respectively). Multiple linear regression showed a strong negative association between serum androstenedione and insulin sensitivity. The incidence of dysglycemia according to an oral glucose tolerance test increased with the severity of androgen phenotype (NA/NT, 0%; HA/NT, 14%; HA/HT, 25%, P = .03). CONCLUSION: Simultaneous measurement of serum T and A represents a useful tool for predicting metabolic risk in PCOS women. HA levels are a sensitive indicator of PCOS-related androgen excess. Endocrine Society 2014-03 2014-01-07 /pmc/articles/PMC3955250/ /pubmed/24423344 http://dx.doi.org/10.1210/jc.2013-3399 Text en Copyright © 2014 by The Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Endocrine Research
O'Reilly, Michael W.
Taylor, Angela E.
Crabtree, Nicola J.
Hughes, Beverly A.
Capper, Farfia
Crowley, Rachel K.
Stewart, Paul M.
Tomlinson, Jeremy W.
Arlt, Wiebke
Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
title Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
title_full Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
title_fullStr Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
title_full_unstemmed Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
title_short Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
title_sort hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione
topic Endocrine Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955250/
https://www.ncbi.nlm.nih.gov/pubmed/24423344
http://dx.doi.org/10.1210/jc.2013-3399
work_keys_str_mv AT oreillymichaelw hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT taylorangelae hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT crabtreenicolaj hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT hughesbeverlya hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT capperfarfia hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT crowleyrachelk hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT stewartpaulm hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT tomlinsonjeremyw hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione
AT arltwiebke hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione